At close: December 20 at 4:00:01 PM EST
After hours: December 20 at 4:44:43 PM EST
Research Analysis
Earnings Estimate
Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 5 | 2 | 5 | 4 |
Avg. Estimate | -0.28 | -0.19 | -1.46 | -0.55 |
Low Estimate | -0.42 | -0.3 | -1.71 | -0.95 |
High Estimate | -0.19 | -0.09 | -1.27 | -0.25 |
Year Ago EPS | -0.53 | -0.44 | -1.48 | -1.46 |
Revenue Estimate
Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 3 | 2 | 4 | 4 |
Avg. Estimate | 710.33k | 2.11M | 7.74M | 14.75M |
Low Estimate | 335k | 1M | 7.2M | 8.7M |
High Estimate | 1.3M | 3.22M | 8.5M | 25M |
Year Ago Sales | 1.99M | 3.83M | 5.12M | 7.74M |
Sales Growth (year/est) | -64.27% | -44.89% | 51.13% | 90.44% |
Earnings History
Currency in USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
---|---|---|---|---|
EPS Est. | -0.56 | -0.44 | -0.4 | -0.39 |
EPS Actual | -0.53 | -0.44 | -0.37 | -0.49 |
Difference | 0.03 | 0 | 0.03 | -0.1 |
Surprise % | 5.69% | 0.00% | 7.96% | -26.45% |
EPS Trend
Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | -0.28 | -0.19 | -1.46 | -0.55 |
7 Days Ago | -0.3 | 0 | -1.48 | -0.67 |
30 Days Ago | -0.3 | 0 | -1.48 | -0.67 |
60 Days Ago | -0.31 | 0 | -1.47 | -0.77 |
90 Days Ago | -0.37 | 0 | -1.54 | -0.86 |
EPS Revisions
Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | 1 |
Up Last 30 Days | -- | -- | -- | 1 |
Down Last 7 Days | 1 | -- | 1 | -- |
Down Last 30 Days | 1 | -- | 1 | 1 |
Growth Estimates
Current Qtr. | Next Qtr. | Current Year | Next Year | |
---|---|---|---|---|
VRCA | 46.42% | 55.68% | 1.08% | 62.26% |
S&P 500 | 5.00% | 12.00% | 2.10% | 12.20% |
Upgrades & Downgrades
Reiterates | Needham: Hold to Hold | 12/20/2024 |
Downgrade | HC Wainwright & Co.: Buy to Neutral | 11/6/2024 |
Reiterates | Needham: Hold | 11/5/2024 |
Downgrade | RBC Capital: Outperform to Sector Perform | 11/5/2024 |
Maintains | TD Cowen: Buy to Buy | 10/21/2024 |
Maintains | RBC Capital: Outperform to Outperform | 10/4/2024 |
Related Tickers
SYRS Syros Pharmaceuticals, Inc.
0.2000
-0.89%
TSHA Taysha Gene Therapies, Inc.
1.8500
0.00%
SCPH scPharmaceuticals Inc.
3.3900
+2.42%
ZNTL Zentalis Pharmaceuticals, Inc.
3.0000
+2.39%
ALXO ALX Oncology Holdings Inc.
1.6200
+9.46%
STRO Sutro Biopharma, Inc.
1.8800
+3.30%
INZY Inozyme Pharma, Inc.
2.9900
+6.41%
MIST Milestone Pharmaceuticals Inc.
1.8000
+4.96%
BCYC Bicycle Therapeutics plc
14.68
-2.13%
PEPG PepGen Inc.
3.6300
-11.25%